Takeda Pharmaceutical Co Ltd
TSE:4502
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3 903
4 482
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Takeda Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
Net Issuance of Common Stock
Takeda Pharmaceutical Co Ltd
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Net Issuance of Common Stock
-¥1.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
13%
|
CAGR 10-Years
20%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Net Issuance of Common Stock
-¥120.1B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-349%
|
CAGR 10-Years
-128%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Net Issuance of Common Stock
-¥20B
|
CAGR 3-Years
-2 616%
|
CAGR 5-Years
-625%
|
CAGR 10-Years
N/A
|
|
|
S
|
Shionogi & Co Ltd
TSE:4507
|
Net Issuance of Common Stock
-¥55.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Net Issuance of Common Stock
¥212m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-15%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Net Issuance of Common Stock
-¥7B
|
CAGR 3-Years
8%
|
CAGR 5-Years
45%
|
CAGR 10-Years
19%
|
|
Takeda Pharmaceutical Co Ltd
Glance View
Takeda Pharmaceutical Co. Ltd. stands as a formidable player in the global healthcare landscape, firmly established as Japan's largest pharmaceutical company. Founded in 1781, Takeda has built a rich legacy of innovation and patient-centricity, evolving from a traditional medicine distributor into a leader in biopharmaceuticals. The company primarily focuses on therapeutic areas such as oncology, gastroenterology, neuroscience, and rare diseases, thus targeting critical health challenges faced by patients worldwide. Takeda's commitment to research and development, underscored by significant investments, facilitates the discovery of new treatments and the enhancement of existing therapies. This forward momentum is particularly noteworthy as it aligns with the growing demand for advanced medications and biologics, positioning Takeda favorably in a competitive market. In recent years, Takeda has strategically expanded its global footprint through key acquisitions, most notably the purchase of Shire in 2019, which significantly enhanced its portfolio in rare diseases. For investors, this positions Takeda not just as a pharmaceutical giant, but as an agile and innovative entity eager to meet the evolving needs of healthcare. With a robust pipeline that promises a mix of newly launched therapeutics and a focus on sustainable growth, Takeda showcases its resilience in navigating the pharmaceutical industry's challenges. The company's dedication to fostering partnerships, along with its ethical approach to business, further strengthens its reputation as a trustworthy investment in the pharmaceutical sector. For investors looking for a blend of historical stability and future potential in a company deeply committed to health and well-being, Takeda stands out as a compelling choice.
See Also
What is Takeda Pharmaceutical Co Ltd's Net Issuance of Common Stock?
Net Issuance of Common Stock
-1.9B
JPY
Based on the financial report for Sep 30, 2024, Takeda Pharmaceutical Co Ltd's Net Issuance of Common Stock amounts to -1.9B JPY.
What is Takeda Pharmaceutical Co Ltd's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 10Y
20%
Over the last year, the Net Issuance of Common Stock growth was 19%. The average annual Net Issuance of Common Stock growth rates for Takeda Pharmaceutical Co Ltd have been 10% over the past three years , 13% over the past five years , and 20% over the past ten years .
You don't have any saved screeners yet
